Articles

O.6 Multipotent mesenchymal stromal cells for poor graft function after allogeneic hematopoietic cell transplantation – a multicenter prospective study

BJH - volume 11, issue Abstract Book BHS, february 2020

S. Servais MD, PhD, F. Baron MD, PhD, C. Lechanteur PhD, E. Baudoux MD, A. Briquet PhD, D. Selleslag MD, J. Maertens MD, PhD, X. Poiré MD, W. Schroyens MD, PhD, C. Graux MD, PhD, A. De Becker MD, R. Schots MD, PhD, P. Zachée MD, PhD, A. Ory , J. Herman , T. Kerre MD, PhD, Y. Beguin MD, PhD

Read more

PP42 Th17 impact on xenogeneic graft-versus-host disease

BJH - 2018, issue Abstract Book BHS, february 2018

L. Delens , G. Ehx , L. Vrancken , G. Fransolet , C. Grégoire MD, M. Hannon , S. Dubois , C. Daulne , Y. Beguin MD, PhD, F. Baron MD, PhD, S. Servais MD, PhD

Read more

PP43 Graft-versus-host disease (GVHD) of the central nervous system (CNS) after allogeneic hematopoietic cell transplantation (alloHCT): case report

BJH - 2018, issue Abstract Book BHS, february 2018

M. Pirotte , F. Forte , L. Lutteri , B. Otto , E. Willems MD, PhD, L. Belle , F. Baron MD, PhD, Y. Beguin MD, PhD, P. Maquet , O. Bodard , S. Servais MD, PhD

Read more

Multiple myeloma bone disease: from mechanisms to next generation therapy

BJH - volume 8, issue 2, march 2017

R. Heusschen PhD, J. Muller MSc, N. Withofs MD, PhD, F. Baron MD, PhD, Y. Beguin MD, PhD, J. Caers MD, PhD

SUMMARY

Multiple myeloma bone disease is a major cause of morbidity and mortality in multiple myeloma patients and persists even in patients in remission. Multiple myeloma bone disease is caused by an uncoupling of bone remodelling, with increased osteoclast activity and decreased osteoblast activity, culminating in lytic bone destruction. Bisphosphonates are the current standard-of-care but new therapies are needed. As the molecular mechanisms controlling multiple myeloma bone disease are increasingly understood, new therapeutic targets are extensively explored in the preclinical setting and initial clinical trials with novel compounds show promising results. In this review, we provide a comprehensive overview of the biology of multiple myeloma bone disease, summarise its current clinical management and discuss preclinical and clinical data on next generation therapies.

(BELG J HEMATOL 2017;8(2):66–74)

Read more

PP50 Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice

BJH - volume 8, issue Abstract Book BHS, february 2017

G. Ehx , G. Fransolet , L. Delens , J. Muller MSc, Y. Beguin MD, PhD, S. Humblet-Baron , M. Hannon , F. Baron MD, PhD

Read more

PP71 Impact of Tofacitinib on xenogeneic graft versus host disease

BJH - volume 8, issue Abstract Book BHS, february 2017

M. Hannon , C. Grégoire MD, J. Muller MSc, G. Fransolet , L. Delens , Y. Beguin MD, PhD, G. Ehx , F. Baron MD, PhD

Read more

PP74 Limited impact of imatinib in a murine model of sclerodermatous chronic graft-versus-host disease

BJH - volume 8, issue Abstract Book BHS, february 2017

G. Fransolet , L. Belle , J. Somja MD, M. Binsfeld , P. Delvenne , P. Drion , M. Hannon , Y. Beguin MD, PhD, G. Ehx , F. Baron MD, PhD

Read more